Search
Atopic Dermatitis Clinical Trials
A listing of 59 Atopic Dermatitis clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 59
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Atopic Dermatitis
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
There are currently 59 active clinical trials seeking participants for Atopic Dermatitis research studies. The states with the highest number of trials for Atopic Dermatitis participants are California, Florida, Texas and Ontario.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Clinical Study
Recruiting
We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Conditions:
Cough
Chronic Cough
Asthma
Allergic Asthma
Sinusitis
Featured Trial
Transcranial Magnetic Stimulation (TMS) for Obsessive Compulsive Disorder (OCD)
Recruiting
Transcranial magnetic stimulation (TMS) is an FDA-approved, non-invasive form of brain stimulation for OCD. TMS has been shown to be an effective form of treatment in individuals with OCD. By using a form of TMS termed theta-burst stimulation (TBS), we hope that this will result in a more effective treatment by producing faster symptom reduction. We are trialing a novel form of accelerated TMS, where we will deliver ten 10-minute sessions per day, for 5 days. This study will compare the efficacy of TMS for OCD at two distinct brain regions. Participants will be randomized into one of two study groups, and receive stimulation at either the DMPFC or R-OFC. Both regions have been linked to OCD by research. Patients that don't respond to their study region will have the option to receive stimulation at the other region.
Conditions:
Obsessive-Compulsive Disorder
Obsessive Compulsive Disorder
Obsessive Compulsive Disorder (OCD)
Obsessive-Compulsive Disorder (OCD)
Obsessive-compulsive Disorders and Symptoms
Featured Trial
High Triglyceride Clinical Research Study
Recruiting
Living with high triglycerides? See if our clinical study is right for you.
Don’t let financial stress hold you back. All clinical study-related assessments, care, and the investigational study drug are available at no cost. You could also be eligible for compensation for travel.
Don’t let financial stress hold you back. All clinical study-related assessments, care, and the investigational study drug are available at no cost. You could also be eligible for compensation for travel.
Conditions:
High Triglycerides
High Triglyceride Level
Hypertriglyceridemia
Elevated Triglycerides
Triglycerides High
Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis
Recruiting
This is a multi-center, longitudinal study which will characterize the gene expression profiles and transcriptomic endotypes that underlie mild and moderate-severe Atopic dermatitis (AD) and will determine changes in these expression patterns and endotypes in response to standard-of-care treatment. Participants will complete up to ten scheduled study visits with assessment of topical steroid response and dupilumab response (if uncontrolled with topical steroids). Skin samples will be collected a... Read More
Gender:
ALL
Ages:
6 years and above
Trial Updated:
01/30/2025
Locations: University of California, San Diego: Dermatology Clinical Trials Unit, La Jolla, California +9 locations
Conditions: Atopic Dermatitis
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
Recruiting
Background:
The immune system is the part of the body that fights infection. Some people have immune deficiencies that cause skin rashes, make them get sick often with infections, or make it difficult for their skin to heal. Researchers want to learn more to better treat conditions that affect immune response.
Objective:
To learn about how the immune system and skin healing are related to each other.
Eligibility:
People ages 18-75 with primary immune deficiency, eczema, or psoriasis. Health... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/30/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Recruiting
The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18 years of age with moderate-to-severe atopic dermatitis (AD).
Gender:
ALL
Ages:
Between 6 months and 17 years
Trial Updated:
01/30/2025
Locations: Clinical Research Center of Alabama, Birmingham, Alabama +98 locations
Conditions: Atopic Dermatitis, Eczema
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
Recruiting
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
01/30/2025
Locations: Anaheim Clinical Trials, LLC, Anaheim, California
Conditions: Healthy Participants, Atopic Dermatitis
A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
Recruiting
The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB1381 (intravenous and subcutaneous) in healthy study participants and after repeat intravenous dosing in study participants with atopic dermatitis. Efficacy will be assessed following repeat intravenous dosing versus placebo in study participants with atopic dermatitis.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/30/2025
Locations: Up0110 117, North Little Rock, Arkansas +23 locations
Conditions: Atopic Dermatitis
Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
Recruiting
Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Corvus Clinical Trials Information, Burlingame, California
Conditions: Atopic Dermatitis
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
Recruiting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD.
Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This stud... Read More
Gender:
ALL
Ages:
Between 18 years and 63 years
Trial Updated:
01/27/2025
Locations: Clinical Trials Institute - Northwest Arkansas /ID# 267290, Fayetteville, Arkansas +81 locations
Conditions: Atopic Dermatitis
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
Recruiting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study compares upadacitinib to dupilumab in pediatric participants with moderate to severe AD who are candidates for systemic therapy. Adverse events and change in the disease activity will be assessed.
Upadacitinib is an approved drug... Read More
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
01/27/2025
Locations: Applied Research Center Of Arkansas /ID# 268547, Little Rock, Arkansas +80 locations
Conditions: Atopic Dermatitis
Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT
Recruiting
The goal of this observational study is to learn about exposure to tralokinumab during pregnancy, as well as atopic dermatitis (AD) during pregnancy.
The main question the study aims to answer is whether pregnant people who have been exposed to tralokinumab during pregnancy experience any differences in pregnancy and infant outcomes compared to women with atopic dermatitis who have not been exposed to tralokinumab during pregnancy. Participants are not required to take tralokinumab during the s... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
01/26/2025
Locations: University of California San Diego (UCSD), La Jolla, California
Conditions: Atopic Dermatitis, Eczema
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
Recruiting
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2025
Locations: Lynn Institute of the Ozarks, Little Rock, Arkansas +99 locations
Conditions: Atopic Dermatitis
The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.
Recruiting
The purpose of the study is to evaluate the effect of ruxolitinib cream on sleep disturbances with participants with Atopic Dermatitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2025
Locations: First Oc Dermatology, Fountain Valley, California +29 locations
Conditions: Atopic Dermatitis
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
Recruiting
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
01/22/2025
Locations: Cahaba Dermatology and Skin Health Center, Birmingham, Alabama +513 locations
Conditions: Atopic Dermatitis
1 - 12 of 59